Annapurna Therapeutics Limited
Annapurna Therapeutics Limited is a gene therapy company focused on discovering and developing new therapeutic products for people living with severe diseases. Annapurna's product pipeline includes programs for alpha-1 antitrypsin (A1AT) deficiency, hereditary angioedema (HAE), and the cardiomyophathy associated with Friedreich's ataxia and severe allergy.
Annapurna Therapeutics merged with Avalanche Biotechnologies to create Adverum Biotechnologies in May of 2016.
Annapurna Therapeutics Limited has technology licensed from Cornell University. The gene therapy research that sparked the creation of the company came from Weill Cornell Medicine.